Pancreas neuroendokrine tumorer (NET'er) vokser normalt langsomt, og laboratoriet overvåger tumoren for tegn på vækst gennem billeddiagnostiske tests. Patienter med NET-spredning ud af bugspytkirtlen har normalt symptomer som diarré eller hormonelle problemer. De kan bruges til lægemidler såsom octreotid, lanreotid, diazoxid og protonpumpehæmmere, som kan hæmme tumorvækst.
When the patient’s symptoms cannot be controlled or the scan shows signs of tumor growth, further treatment is required, and chemotherapy or targeted drugs (such as sunitinib or everolimus) can be used. For people with poorly differentiated tumors (neuroendocrine carcinoma), chemotherapy is the first choice. For patients who have spread to the liver, choose surgery or ablation technology for treatment according to their own conditions. For adults with somatostatin (a hormone) receptor-positive pancreatic neuroendocrine tumor, the radiopharmaceutical Lutathera (l Lu177 dotatate) is a treatment option.
Hvis alle mulige behandlinger ikke længere virker, så overvej at deltage i kliniske forsøg for at teste nye terapier. Deltagelse i kliniske forsøg vil sandsynligvis gavne nogle patienter.
